Trials / Recruiting
RecruitingNCT04680377
Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patients
Using Microbiome to Predict Durvalumab Toxicity in Post-CCRT NSCLC Patients (Microdurva)
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 44 (estimated)
- Sponsor
- Jun Zhang, MD, PhD · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This phase IV study is hoping to determine if examining the microbiome in non-small cell lung cancer participants who will receive durvalumab can predict treatment toxicity.
Conditions
Timeline
- Start date
- 2021-04-12
- Primary completion
- 2025-12-01
- Completion
- 2026-12-01
- First posted
- 2020-12-23
- Last updated
- 2024-05-08
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT04680377. Inclusion in this directory is not an endorsement.